Loading
Ferroptosis and Cancer Prognosis · Journal article
Biomedicine & Pharmacotherapy · August 15, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review proposing a theoretical mechanistic model—the Hypoxia–STAT3–LIV1–zinc signaling axis—as a central driver of TNBC progression and therapeutic resistance. The model integrates previously established but independently studied pathways into a unified hypothesis and suggests experimental and translational strategies to test it; no new clinical or experimental evidence is presented to validate the proposed mechanism.
Journal article. Triple-negative breast cancer; no specific clinical population studied.
Hypoxia stabilizes HIF-1α, promoting STAT3 activation and LIV-1 expression in TNBC Elevated intracellular zinc sustains STAT3 phosphorylation through inhibition of negative regulatory phosphatases The proposed axis enhances epithelial-mesenchymal transition, cancer stemness, immune modulation and treatment resistance
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review outlines a testable mechanistic hypothesis that could guide future biomarker discovery and drug development in TNBC, but presents no evidence sufficient to change clinical practice or guide immediate treatment decisions. Clinicians should view this as a framework for understanding TNBC biology rather than actionable clinical guidance.
A mechanistic review proposing an integrated signaling model in TNBC based on existing evidence, without presenting new experimental data or clinical validation.
This review outlines a testable mechanistic hypothesis that could guide future biomarker discovery and drug development in TNBC, but presents no evidence sufficient to change clinical practice or guide immediate treatment decisions. Clinicians should view this as a framework for understanding TNBC biology rather than actionable clinical guidance.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Triple-negative breast cancer remains one of the most aggressive and therapeutically challenging breast cancer subtypes because of its high metastatic potential, molecular heterogeneity and limited targeted treatment options. Hypoxia is a hallmark of TNBC tumor microenvironment and activates signaling cascades that promote tumor progression, metastasis, immune evasion, and therapeutic resistance. Although hypoxia, STAT3 signaling, LIV-1 (SLC39A6), and zinc homeostasis have been independently implicated in TNBC progression, the mechanistic crosstalk among these pathways and their integration into a unified, subtype specific model remains insufficiently understood. Emerging evidence suggests that LIV-1 functions not merely as a zinc transporter but as an active regulator of oncogenic signaling. Under hypoxia conditions, stabilization of hypoxia-inducible factor-1α (HIF-1α) promotes cytokine- mediated STAT3 activation, leading to increased LIV-1 expression and consequent intracellular zinc accumulation. Elevated zinc levels, in turn, may sustain STAT3 phosphorylation through inhibition of negative regulatory phosphatases, establishing a self-reinforcing feed-forward loop that enhances epithelial-mesenchymal transition, cancer stemness, immune modulation and treatment resistance. Current TNBC therapies, including chemotherapy and emerging immunotherapies show limited durable efficacy, underscoring the need for mechanistically grounded biomarkers and targets. Based on these observations, we propose the Hypoxia–STAT3–LIV-1–zinc signaling axis as a central regulatory node driving TNBC progression and a promising candidate for biomarker development and therapeutic targeting. This review integrates current evidence supporting this signaling network, identifies critical knowledge gaps, and outlines experimental strategies including hypoxia-mimetic models, LIV-1/STAT3 knockdown systems, and zinc chelation assays needed to validate this proposed mechanism and translate it into clinical application.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.